Mylan Recalls a Second Batch of Insulin Glargine
This is the second batch to be recalled because of the potential of missing labels.
Mylan Pharmaceuticals, a Viatris company, is recalling another batch of Insulin Glargine (insulin glargine-yfgn) injection, this time 3 mL prefilled pens packaged in cartons of five pens. This is not the branded Semglee pen but the unbranded Insulin Glargine-yfgn pens. This batch is being recalled due to the potential for the label to be missing on some pens.
Mylan notes that a missing label could lead to a mix-up of products/strengths, which may result in less optimal glycemic control. To date, no adverse events related to this recall have been received for this product.
In April 2022, Mylan recalled one batch of its insulin glargine injection packaged in a carton with 10 mL vials for the same reason.
Related: Mylan Recalls One Batch of Insulin Glargine
The impacted product is this current recall is batch number BF21002895 with an expiration date of August 2023. The NDC number is 49502-394-75. This batch was manufactured by Biocon Sdn. and was distributed by Mylan Specialty in the United States between April 4, 2022, and May 5, 2022.
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
July 25th 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
FDA Extends Review of Blenrep Combinations in Multiple Myeloma
July 24th 2025Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing and tolerability. The new action date is Oct. 23, 2025.
Read More
Sarepta to Pause Shipments of the Gene Therapy Elevidys
July 22nd 2025Sarepta officials said the temporary halt in shipments was done to maintain a productive working relationship with regulators while they address a safety labeling update about the risk of acute liver disease related to Elevidys.
Read More
